you ever invested in biotech or tech looking to commercialise IP. They don’t produce revenue so their only means of progression is raising capital. However 43% of every dollar spent likely palace for R&D grant rebate so that stretches the research dollars 43% further than the technical cash position.
Ann: Investor Presentation, page-3
Add BB1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.013(3.27%) |
Mkt cap ! $21.12M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 41.0¢ | 37.0¢ | $308.1K | 775.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 74999 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 9975 | 1 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
38.0¢ |
Change
-0.013 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 39.5¢ | 41.0¢ | 37.5¢ | 285906 | ||
| Last updated 15.35pm 21/05/2024 ? | |||||
| BB1 (ASX) Chart |